Inhibition of PSTAT3-Y705 alone does not improve glioma resistance to existing therapies, and combined inhibition of PSTAT3-S727 and PSTAT3-Y705 downregulates pathological activation of STAT3 in glioma cells, glioma stem cells, and mesenchymal cells (Ouédraogo et al., 2016). The gene discussed is STAT3; the disease is central nervous system cancer.